eggXYt and Tropic Biosciences Come Together to Fight Avian Influenza Virus in Chickens
By applying GEiGS, eggXYt will extend its portfolio of poultry beyond its initial product and into the area of animal health.
FREMONT, CA: EggXYt, a biotechnology business revolutionizing the livestock industry, and Tropic Biosciences (Tropic), a revolutionary agricultural biotechnological company, announced a license agreement to apply the Tropic Gene Editing Induced Gene Silencing (GEiGS) technology to establish genetic resistance in chickens to the Avian Influenza virus.
Automatically produced Avian Influenza virus is one of the deadliest and most expensive avian diseases. For instance, the 2015 U.S. outbreak resulted in the slaughter of 50 million poultry and is estimated to have had an economic cost of 3.2 billion dollars. Outbreaks not only damage the protein supply chain but also endanger human health, as the disease can be transmitted from birds to humans and has been reported to lead to serious illness and fatality.
Yehuda Elram, CEO and Co-Founder, eggXYt commented, “Our primary goal is to improve animal welfare and efficiency within the poultry industry, and we are excited to embark on this project that broadens our platform of gene editing solutions for animal health.” He went on to say “Following the COVID-19 outbreak, we are all very mindful of the threat of zoonotic diseases to human health and so we are especially motivated to embark on a project that may help to prevent further pandemics.”
EggXYt puts together its proven experience in accelerating gene-editing solutions to disrupt the poultry market. Over the last four years, eggXYt has expanded its flagship product, a groundbreaking solution to determine the pre-incubation sex of chicks, which is intended to save 4 billion male chicks in the egg layer industry that are currently being killed each year because of their incapability to lay eggs and because it is not reasonable to raise them for meat. By applying GEiGS, eggXYt will extend its portfolio of poultry beyond its initial product and into the area of animal health. EggXYt has recently relocated to a state-of-the-art R&D facility and is expected to begin a fundraising round to support its R&D projects and the road to commercialization.
Tropic Biosciences has produced GEiGS to promote the growth of its own tropical crops, such as banana plants that are resistant to Panama disease, a destructive fungal disease that threatens production worldwide. Recognizing the broader potential of GEiGS beyond tropical crops, Tropic has made the patented technology platform commercially accessible to other creative businesses, including world leaders in the farming and livestock industries.
“The GEiGSTM platform harnesses naturally occurring defense mechanisms to directly attack disease agents, solving the heavy burden of target gene discovery for gene editing applications. This is driving extensive interest in the technology from outside parties and we are delighted to partner with eggXYt and other innovative companies from the broader agricultural and life-sciences industries,” commented Eyal Maori, Chief Science Officer, and Co-Founder, Tropic Biosciences.
Tropic and eggXYt’s partnership comes at an exciting time for gene editing, just after Jennifer Doudna and Emmanuelle Charpentier won the CRISPR 2020 Nobel Prize in Chemistry for Growth.